Did you finish first line chemo for stage 3 or ... - My Ovacome

My Ovacome

17,746 members19,983 posts

Did you finish first line chemo for stage 3 or 4 ovarian, fallopian tube or primary peritoneal cancer between 24 Oct 2021 and 24 Aug 2022?

OvacomeSupport profile image
OvacomeSupportPartnerMy Ovacome Team
1 Reply

Good morning all

Have you been diagnosed with stage 3 or 4 ovarian, primary peritoneal or fallopian tube cancer and did you have your last dose of first line chemotherapy sometime between 24 October 2021 and 24 August 2022?

If so, you may be eligible to take part in an important new study which aims to identify areas for improvement in supporting the lives of patients at different stages of their treatment pathway and to contribute to the mutual understanding between patients and their consultants, nurses and surgeons.

As well as looking at the emotional and physical effects felt by patients after treatment, it will investigate whether clinicians understand these challenges and how they might be supported to address the clinical and emotional needs of those they treat.

This study involves completing a survey. This is non-interventional observational study, meaning that participants will not receive any treatment as part of the study.

All study participants will receive £50 on successful completion of the survey.

Here is some further information about criteria for participation:

• You must have received treatment in the UK.

• You must be over 18.

• You must have been diagnosed with epithelial ovarian cancer (high grade serous, low grade serous, endometrioid, clear cell, mucinous), fallopian tube cancer, or primary peritoneal cancer.

• You must have been diagnosed at stage 3 or 4.

• As first line treatment you must have had either:

• Chemotherapy only

• Surgery and then chemotherapy

• Chemotherapy, followed by surgery, followed by more chemotherapy

• You must have finished your first line chemotherapy treatment between two and 12 months prior to taking part in the survey.

If you would like to know more about this study, please visit ovacome.org.uk/news/patron.

If you would like to participate in this study please contact Serena Lavin at the fieldwork agency via 01625 668988 or serena.lavin@defactoresearch.com

To learn more, you can also contact the Ovacome support team on 0800 008 7054 or by emailing support@ovacome.org.uk. Please don’t hesitate to get in touch if we can help with any further information or if there is anything we can do to support your participation.

If you have already completed the study or aren't eligible to participate, it would be much appreciated if you could share details of the study with your clinical teams or any contacts who may be eligible to take part.

Best wishes,

Jo

Ovacome Support

Written by
OvacomeSupport profile image
OvacomeSupport
Partner
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Viktoria11 profile image
Viktoria11

Hello everybody,

I was diagnosed ovarian cancer stage 3(C), I have had 9 courses chemotherapy totally but I don't correspond to your criteria for participation.

I had all my treatment in Ukraine and when the russian fascists started the war in February, unfortunately, my chemo was terminated. Now I fight with my country for Victory!

My best regards

You may also like...

NICE review olaparib and bevacizumab - your comments needed

treatment plan for ovarian, fallopian tube or peritoneal cancer or if you have received this in the...

Rucaparib - your experiences needed

maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer...

NICE review of first-line olaparib - your comments needed

hear from you if you are currently receiving olaparib as part of your treatment plan for ovarian,...

Niraparib - NICE appraisal

recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to...

Rucaparib - NICE appraisal

email support@ovacome.org.uk or call 0800 0087054. In particular, if you took Rucaparib as part of...